FRANKFURT, June 23 (Reuters) - German drugs and chemicals group Merck KGaA (MRCG.DE: Quote, Profile, Research) suffered a major setback in its drug pipeline on Friday as it dropped development of sarizotan, one of its few new medicines in late-phase clinical trials.
